tiprankstipranks
Trending News
More News >
Geron Corp (GERN)
NASDAQ:GERN
US Market
Advertisement

Geron (GERN) Earnings Dates, Call Summary & Reports

Compare
2,529 Followers

Earnings Data

Report Date
Mar 12, 2026
After Close (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
-0.03
Last Year’s EPS
-0.04
Same Quarter Last Year
Based on 5 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 05, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The earnings call reflects a mixed sentiment with both positive developments in terms of increased prescribing accounts and new patient starts, as well as financial stability. However, there are significant challenges with declining demand, issues with late-line discontinuations, and the need for increased awareness and education on RYTELO's earlier line use.
Company Guidance
During the Geron Corporation Third Quarter 2025 Earnings Call, the company provided detailed guidance on their performance and future strategies, focusing on the commercial potential of RYTELO in treating lower-risk myelodysplastic syndromes (MDS). Key financial metrics revealed net product revenue of $47.2 million for Q3, despite a 3% decline in demand from the previous quarter. The number of new patient starts increased from 30% to 36% compared to Q2, although this was offset by discontinuations in later-line patients. Geron expanded its prescribing accounts by 15%, adding approximately 150 new ordering accounts, bringing the total to 1,150. The company highlighted its strong cash position of approximately $420 million and anticipated that its financial resources would support future engagement and expansion strategies. Geron also outlined plans for the European market, with commercialization of RYTELO in select EU markets planned for 2026. The company emphasized the need for increased awareness among U.S. healthcare providers to improve RYTELO's utilization and recognized that execution improvements would take time, projecting revenue growth primarily in 2026.
Increased Prescribing Accounts
Prescribing accounts increased by 15% in Q3, with approximately 150 new ordering accounts added, expanding the footprint to 1,150 accounts.
Improvement in New Patient Starts
New patient starts in the first and second line increased to 36%, up from 30% in Q2.
Strong Financial Position
Geron remains well-capitalized with $420 million in cash and marketable securities, and expects to have sufficient resources to fund projected operating expenses.
Presence at Medical Conferences
Active participation in hematology forums such as the Society of Hematologic Oncology Conference and upcoming ASH conference to increase RYTELO's awareness and engagement.

Geron (GERN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

GERN Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Mar 12, 2026
2025 (Q4)
-0.03 / -
-0.04
Nov 05, 2025
2025 (Q3)
-0.03 / -0.03
-0.0425.00% (+0.01)
Aug 06, 2025
2025 (Q2)
-0.03 / -0.02
-0.180.00% (+0.08)
May 07, 2025
2025 (Q1)
-0.04 / -0.03
-0.0966.67% (+0.06)
Feb 26, 2025
2024 (Q4)
-0.03 / -0.04
-0.0955.56% (+0.05)
Nov 07, 2024
2024 (Q3)
-0.08 / -0.04
-0.0850.00% (+0.04)
Aug 08, 2024
2024 (Q2)
-0.10 / -0.10
-0.09-11.11% (-0.01)
May 02, 2024
2024 (Q1)
-0.10 / -0.09
-0.07-28.57% (-0.02)
Feb 28, 2024
2023 (Q4)
-0.10 / -0.09
-0.110.00% (+0.01)
Nov 02, 2023
2023 (Q3)
-0.10 / -0.08
-0.120.00% (+0.02)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

GERN Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 05, 2025
$1.15$1.09-5.22%
Aug 06, 2025
$1.20$1.39+15.83%
May 07, 2025
$1.32$1.31-0.76%
Feb 26, 2025
$2.37$1.61-32.07%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Geron Corp (GERN) report earnings?
Geron Corp (GERN) is schdueled to report earning on Mar 12, 2026, After Close (Confirmed).
    What is Geron Corp (GERN) earnings time?
    Geron Corp (GERN) earnings time is at Mar 12, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is GERN EPS forecast?
          GERN EPS forecast for the fiscal quarter 2025 (Q4) is -0.03.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis